Physician profile
David Kim
NPI 1255696225
$8,444.39
in general payments reported to CMS, 2019-2025
24 companies · $1,989 in 2025
The $1,989 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $46.73 · 2021: $741 · 2022: $2,158 · 2023: $1,907 · 2024: $1,227 · 2025: $1,989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,122.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,664.31 | 2021-2025 | Micra, Selectsite, Aurora Ev-Icd Mri Surescan |
| Boston Scientific Corporation | $1,162.77 | 2019-2025 | Emblem Mri S-Icd, General - Therapies, Lux-Dx Insertable Cardiac Monitor |
| Biosense Webster, INC. | $991.44 | 2021-2025 | Carto 3, Qdot Micro Catheter |
| Novartis Pharmaceuticals Corporation | $406.52 | 2019-2025 | |
| Aop Health US, LLC | $323.00 | 2025 | Rapiblyk |
| Pfizer INC. | $307.55 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $216.86 | 2022-2025 | Brilinta, Farxiga, Wainua |
| E.R. Squibb & Sons, L.L.C. | $189.72 | 2023-2025 | Camzyos, Eliquis |
| Elutia, INC. | $176.84 | 2021 | |
| Biotronik INC. | $171.39 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.05 | 2022-2025 | Jardiance |
| Medtronic Vascular, INC. | $148.27 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $117.62 | 2025 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $116.26 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $55.17 | 2025 | Lifevest |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Altathera Pharmaceuticals LLC | $48.14 | 2024-2025 | Sotalol Hydrochloride |
| Genzyme Corporation | $35.00 | 2024 | |
| Alnylam Pharmaceuticals INC. | $25.62 | 2025 | |
| Lilly USA, LLC | $23.05 | 2025 | Zepbound, Mounjaro |
| Amgen INC. | $22.06 | 2024 | |
| Sanofi-Aventis U.S. LLC | $19.01 | 2023 | |
| Abbvie INC. | $18.77 | 2022 | |
| Sensible Medical Innovations INC | $18.22 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.75 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.